ClinicalTrials.gov
ClinicalTrials.gov Menu

Selenoprotein P and Non-alcoholic Fatty Liver Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01257685
Recruitment Status : Completed
First Posted : December 10, 2010
Last Update Posted : December 10, 2010
Sponsor:
Information provided by:
Korea University

Brief Summary:

The pathogenesis of nonalcoholic fatty liver disease has not been fully elucidated. The most widely supported theory implicates insulin resistance as the key mechanism leading to hepatic steatosis, and perhaps also to steatohepatitis.

Selenoprotein P(SeP) is a secretory protein primarily produced by the liver. Previous studies demonstrated that SeP, a liver-derived secretory protein, causes insulin resistance.

Therefore, the purpose of this study is to determine the different Sep levels between healthy normal group and NAFLD group.


Condition or disease
Non-Alcoholic Fatty Liver Disease Insulin Resistance

Study Type : Observational
Actual Enrollment : 120 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Selenoprotein P and Non-alcoholic Fatty Liver Disease
Study Start Date : September 2007
Actual Primary Completion Date : August 2008
Actual Study Completion Date : August 2008


Group/Cohort
Control Group
NAFLD Group



Primary Outcome Measures :
  1. Selenoprotein P

Secondary Outcome Measures :
  1. DXA-measured trunk fat mass
  2. CT-measured visceral fat area


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy volunteers for visiting routine medical check in our clinic
Criteria

Inclusion Criteria:

  • Healthy volunteers for visiting routine medical check in our clinic

Exclusion Criteria:

  • History of cardiovascular disease(myocardial infarction, unstable angina, or cardiovascular revascularization)
  • Diabetes
  • Hypertension
  • Malignancy
  • Severe renal or hepatic disease
  • Subjects taking medications that might affect body weight or body composition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01257685


Locations
Korea, Republic of
Hae Yoon Choi
Seoul, Korea, Republic of, 152-703
Sponsors and Collaborators
Korea University
Investigators
Study Director: Kyung Mook Choi, MD.PhD Korea University

Responsible Party: Kyung Mook Choi, Korea university
ClinicalTrials.gov Identifier: NCT01257685     History of Changes
Other Study ID Numbers: SEPP1(NAFLD)
First Posted: December 10, 2010    Key Record Dates
Last Update Posted: December 10, 2010
Last Verified: December 2010

Additional relevant MeSH terms:
Insulin Resistance
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Digestive System Diseases